Advertisement
Screener

Aurinia Pharmaceuticals Inc. (AUPH) Graph

AUPH Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $83.22M; Cost of revenue $6.55M; Research and development $13.05M; Operating expenses (m).
  • 2026-03-31: Revenue $77.70M; Cost of revenue $6.50M; Research and development $7.47M; Operating expenses (m).
  • 2025-12-31: Revenue $77.11M; Cost of revenue $8.80M*; Research and development $10.89M*; Operating expenses $43.88M.
  • 2025-09-30: Revenue $73.47M; Cost of revenue $8.18M; Research and development $8.44M; Operating expenses $43.72M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AUPH revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$79.41MLicense CollaborationAnd Royalty Revenue$3.81MRevenue$83.22MCost of revenue$6.56MOperating income$46.34MResearch & development$13.05MPre-tax income$48.79MNet income$37.41M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$83.22M$6.55M$13.05M(m)$11.37M$37.41M
2026-03-31$77.70M$6.50M$7.47M(m)$9.57M$34.35M
2025-12-31$77.11M$8.80M*$10.89M*$43.88M-$175.10M*$210.79M
2025-09-30$73.47M$8.18M$8.44M$43.72M$411.00K$31.55M
2025-06-30$70.01M$7.12M$7.43M$49.92M$643.00K$21.51M
2025-03-31$62.47M$8.57M$5.74M$40.62M$1.00M$23.34M
2024-12-31$59.87M(m)(m)$61.54M(m)$1.43M
2024-09-30$67.77M$6.04M$3.05M$56.02M$457.00K$14.35M
2024-06-30$57.19M$8.91M$4.08M$58.70M$756.00K$722.00K
2024-03-31$50.30M$7.75M$5.55M$63.56M$739.00K-$10.75M
2023-12-31$45.09M(m)(m)$74.77M(m)-$26.88M
2023-09-30$54.52M$6.77M$13.61M$70.78M$298.00K-$13.45M
2023-06-30$41.49M$1.56M$12.65M$57.66M-$642.00K-$11.49M
2023-03-31$34.41M$421.00K$13.16M$63.99M$436.00K-$26.21M
2022-12-31$28.43M(m)(m)$56.53M(m)-$26.05M
2022-09-30$55.78M$2.45M$10.97M$65.28M$954.00K-$8.99M
2022-06-30$28.19M$1.60M$11.53M$64.18M$9.00K-$35.52M
2022-03-31$21.63M$256.00K$12.62M$59.51M$10.00K-$37.63M
2021-12-31$23.40M(m)(m)$56.11M(m)-$33.32M
2021-09-30$14.67M$254.00K$20.07M$65.02M$8.00K-$50.26M
2021-06-30$6.62M$308.00K$10.09M$53.75M$18.00K-$47.01M
2021-03-31$914.00K$48.00K$9.83M$51.46M$8.00K-$50.38M
2020-12-31$50.03M(m)(m)$58.08M(m)-$8.07M
2020-09-30$29.00K$0.00$12.24M$42.34M-$15.00K-$42.13M
2020-06-30$29.00K$0.00$11.08M$26.89M$2.00K-$26.54M
2020-03-31$30.00K$0.00$13.84M$27.09M-$238.00K-$25.93M
2019-12-31$29.00K(m)(m)$34.87M(m)-$34.46M
2019-09-30$230.00K(m)(m)$24.30M(m)-$23.45M
2019-06-30$29.00K(m)(m)$17.17M(m)-$16.38M
2019-03-31$30.00K(m)(m)$14.92M(m)-$14.10M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2026-06-30$160.93M$13.06M$20.52M$20.94M$71.77M
2025-06-30$132.47M$15.69M$13.18M$1.65M$44.86M
2024-06-30$107.50M$16.66M$9.63M$1.50M-$10.03M
2023-06-30$75.90M$1.98M$25.81M-$206.00K-$37.70M
2022-06-30$49.82M$1.85M$24.14M$19.00K-$73.14M
2021-06-30$7.53M$356.00K$19.92M$26.00K-$97.39M
2020-06-30$59.00K$0.00$24.91M-$236.00K-$52.48M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2025-09-30$205.94M$23.87M$21.61M$2.06M$76.41M
2024-09-30$175.27M$22.70M$12.68M$1.95M$4.32M
2023-09-30$130.42M$8.75M$39.41M$92.00K-$51.15M
2022-09-30$105.59M$4.30M$35.12M$973.00K-$82.13M
2021-09-30$22.20M$610.00K$39.99M$34.00K-$147.64M
2020-09-30$88.00K$0.00$37.15M-$251.00K-$94.61M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$283.06M$32.66M$32.51M(m)$178.14M-$173.04M$287.20M
2024-12-31$235.13M$28.25M$20.79M(m)$239.82M$1.70M$5.80M
2023-12-31$175.51M$14.15M$49.64M$195.00M$267.20M$551.00K-$78.00M
2022-12-31$134.03M$5.66M$44.99M$196.40M(m)$1.83M-$108.20M
2021-12-31$45.60M$1.09M$51.14M$173.50M(m)$760.00K-$181.00M
2020-12-31$50.12M$0.00$50.33M$97.30M$154.41M-$94.00K-$102.68M
2019-12-31$318.00K$0.00$52.87M$22.30M$91.26M$144.00K-$88.39M
2018-12-31$463.00K(m)$41.38M(m)$55.70M$73.00K-$53.08M
2017-12-31(m)(m)$33.93M(m)(m)(m)(m)
2016-12-31(m)(m)$14.53M(m)(m)(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zai Lab Ltd (ZLAB)$2.241B-113.34
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Generate Biomedicines, Inc. (GENB)United States$2.052B